$TCRT
Alaunos Therapeutics, Inc.

2019 Q4 Form 10-Q Financial Statement

#000119312519287259 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.820M $4.810M $4.760M
YoY Change 27.63% 11.6% -2.66%
% of Gross Profit
Research & Development $10.22M $8.641M $9.998M
YoY Change 24.63% 4.57% 33.5%
% of Gross Profit
Depreciation & Amortization $180.0K $150.0K $160.0K
YoY Change 5.88% 0.0% 14.29%
% of Gross Profit
Operating Expenses $16.04M $13.45M $14.75M
YoY Change 25.71% 6.98% 19.19%
Operating Profit -$16.04M -$13.45M -$14.75M
YoY Change 25.65% 6.98% 19.19%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $290.0K $203.0K $133.0K
YoY Change 70.59% 35.33% -18.9%
Pretax Income -$15.75M -$74.00M -$14.62M
YoY Change 26.2% 487.77% 21.53%
Income Tax
% Of Pretax Income
Net Earnings -$15.75M -$74.00M -$14.62M
YoY Change -108.09% 296.57% -16.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.43 -$0.09
Diluted Earnings Per Share -$0.09 -$0.43 -$0.09
COMMON SHARES
Basic Shares Outstanding 181.0M 162.6M 162.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.70M $88.40M $43.60M
YoY Change 29.17% 178.86% 7.92%
Cash & Equivalents $79.74M $88.42M $43.56M
Short-Term Investments
Other Short-Term Assets $22.40M $23.70M $20.80M
YoY Change 8.21% 64.58% 74.79%
Inventory
Prepaid Expenses
Receivables $3.300M $3.400M $1.500M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $105.5M $115.6M $65.86M
YoY Change 25.16% 145.12% 24.28%
LONG-TERM ASSETS
Property, Plant & Equipment $1.110M $828.0K $877.0K
YoY Change 1.19% -38.39% -34.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $110.0K $109.0K $4.869M
YoY Change -98.85% -99.4% -77.8%
Total Long-Term Assets $3.622M $2.350M $7.314M
YoY Change -66.36% -88.03% -68.73%
TOTAL ASSETS
Total Short-Term Assets $105.5M $115.6M $65.86M
Total Long-Term Assets $3.622M $2.350M $7.314M
Total Assets $109.1M $117.9M $73.17M
YoY Change 14.8% 76.57% -4.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $906.0K $926.0K $941.0K
YoY Change 28.15% -27.03% 60.03%
Accrued Expenses $10.85M $9.573M $8.799M
YoY Change 23.77% 2.09% 1.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.53M $11.18M $10.40M
YoY Change 32.09% -81.43% 11.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.600M $600.0K $800.0K
YoY Change -76.92% -98.46%
Total Long-Term Liabilities $1.600M $600.0K $800.0K
YoY Change -76.92% -98.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.53M $11.18M $10.40M
Total Long-Term Liabilities $1.600M $600.0K $800.0K
Total Liabilities $14.10M $11.82M $11.18M
YoY Change 48.67% -81.17% -81.73%
SHAREHOLDERS EQUITY
Retained Earnings -$684.1M -$668.4M -$594.4M
YoY Change 20.8% -12.2% -20.6%
Common Stock $779.1M $774.5M $656.4M
YoY Change 19.52% 28.06% 7.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.01M $106.1M $62.00M
YoY Change
Total Liabilities & Shareholders Equity $109.1M $117.9M $73.17M
YoY Change 14.8% 76.57% -4.2%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$15.75M -$74.00M -$14.62M
YoY Change -108.09% 296.57% -16.42%
Depreciation, Depletion And Amortization $180.0K $150.0K $160.0K
YoY Change 5.88% 0.0% 14.29%
Cash From Operating Activities -$11.60M -$10.93M -$8.090M
YoY Change -1.86% 28.44% -20.45%
INVESTING ACTIVITIES
Capital Expenditures $100.0K $100.0K $70.00K
YoY Change -211.11% -41.18% -69.57%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K -$100.0K -$70.00K
YoY Change -211.11% -41.18% -69.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.030M 55.89M 230.0K
YoY Change -92.67% -174.19%
NET CHANGE
Cash From Operating Activities -11.60M -10.93M -8.090M
Cash From Investing Activities -100.0K -100.0K -70.00K
Cash From Financing Activities 3.030M 55.89M 230.0K
Net Change In Cash -8.670M 44.86M -7.930M
YoY Change -129.27% -616.82% -25.96%
FREE CASH FLOW
Cash From Operating Activities -$11.60M -$10.93M -$8.090M
Capital Expenditures $100.0K $100.0K $70.00K
Free Cash Flow -$11.70M -$11.03M -$8.160M
YoY Change -0.26% 27.07% -21.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
926000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
707000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9573000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8763000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
774324000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
651732000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
115599000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
84285000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88419000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61729000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
181000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
161000
CY2019Q3 us-gaap Assets
Assets
117949000
CY2018Q4 us-gaap Assets
Assets
95051000
CY2019Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
130000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2019Q3 us-gaap Liabilities
Liabilities
11823000
CY2018Q4 us-gaap Liabilities
Liabilities
9487000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117949000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95051000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11176000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9483000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9541000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23739000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20692000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1097000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
828000
CY2019Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
3441000
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1864000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-668379000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-566329000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28115000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25935000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13707000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
106126000
CY2019Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
677000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15355000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
150000
CY2019Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
647000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1283000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
203000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-73996000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12585000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13448000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12570000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
523000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
462000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41822000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41144000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8641000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8263000
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6074000
us-gaap Net Income Loss
NetIncomeLoss
-102050000
us-gaap Net Income Loss
NetIncomeLoss
-40636000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
16656000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4807000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4307000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
13448000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
12570000
us-gaap Operating Expenses
OperatingExpenses
41822000
us-gaap Operating Expenses
OperatingExpenses
41290000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
170613712
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141185404
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
164053029
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141020025
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-146000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-112000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61729000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71335000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88419000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32117000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
17000
us-gaap Depreciation
Depreciation
453000
us-gaap Depreciation
Depreciation
412000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1577000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1002000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3047000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5406000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-9432000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
219000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3148000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
810000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-532000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
545000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-545000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26690000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39218000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4684000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29246000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37638000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1275000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1020000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
240000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
370000
ziop Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
-2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56120000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1035000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7000
ziop Compensation Paid In Restricted Stock Gross
CompensationPaidInRestrictedStockGross
1000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58317741
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26469522
CY2017 ziop License Agreement Commencement Date
LicenseAgreementCommencementDate
2015-05
CY2018 ziop Related Party Transaction Expenses From Transactions With Related Party Advisory Fees
RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
2000000
CY2019Q1 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
2000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
184000
CY2019Q3 us-gaap Lease Cost
LeaseCost
184000
us-gaap Operating Lease Cost
OperatingLeaseCost
585000
us-gaap Lease Cost
LeaseCost
585000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M24D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
188000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
755000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
491000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1434000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
110000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1324000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
723000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
736000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
488000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1947000
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1486000
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1480000
us-gaap Share Based Compensation
ShareBasedCompensation
4741000
us-gaap Share Based Compensation
ShareBasedCompensation
6850000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
140000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
300500
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.05
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.49
CY2019Q1 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
446428
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5277085
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1835755
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1634791
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4995549
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2581327
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3099935
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.24
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.69
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.11
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M2D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6025000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2425000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.15
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M4D
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
88000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3971940
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
482500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.48
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-139235000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1480000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-156414000
CY2018Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6074000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6850000
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-8131000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
16656000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1275000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
61995000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1486000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
420000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
85564000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4741000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1020000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
181030020
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
181030020
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161066136
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161066136
ziop Non Operating Income Expense Inducement Of Warrants
NonOperatingIncomeExpenseInducementOfWarrants
60751000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
2971000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
52499000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60751000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000000
ziop Stock Issued During Period Value Net On Exercise Of Warrants
StockIssuedDuringPeriodValueNetOnExerciseOfWarrants
52499000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-370000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2971000
CY2017 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Precigen and MD Anderson formed a joint steering committee to oversee and manage the new and ongoing research programs. Under the License Agreement with Precigen, the Company and Precigen agreed that Precigen would no longer participate on the joint steering committee after the date of the License Agreement. As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
181030020
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
506000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0139
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0192
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0282
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0298
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7287
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7834
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8227
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8308
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2018Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-165000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
13000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73996000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18659000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-102050000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57292000
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Trading Symbol
TradingSymbol
ZIOP
dei Security12b Title
Security12bTitle
Common Stock
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
dei Entity Shell Company
EntityShellCompany
false
CY2004Q3 ziop Number Of Products
NumberOfProducts
2
CY2019Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1038
CY2019Q3 ziop Non Operating Income Expense Inducement Of Warrants
NonOperatingIncomeExpenseInducementOfWarrants
60751000
ziop Non Operating Income Expense Inducement Of Warrants
NonOperatingIncomeExpenseInducementOfWarrants
60751000
CY2019Q3 ziop Stock Issued During Period Value Net On Exercise Of Warrants
StockIssuedDuringPeriodValueNetOnExerciseOfWarrants
52499000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60751000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2971000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
5741000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
6850000
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000

Files In Submission

Name View Source Status
0001193125-19-287259-index-headers.html Edgar Link pending
0001193125-19-287259-index.html Edgar Link pending
0001193125-19-287259.txt Edgar Link pending
0001193125-19-287259-xbrl.zip Edgar Link pending
d786918d10q.htm Edgar Link pending
d786918dex107.htm Edgar Link pending
d786918dex311.htm Edgar Link pending
d786918dex312.htm Edgar Link pending
d786918dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20190930.xml Edgar Link completed
ziop-20190930.xsd Edgar Link pending
ziop-20190930_cal.xml Edgar Link unprocessable
ziop-20190930_def.xml Edgar Link unprocessable
ziop-20190930_lab.xml Edgar Link unprocessable
ziop-20190930_pre.xml Edgar Link unprocessable